About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ACAD - ACADIA Pharmaceutica...| Previous Close | $20.95 | Open | $20.89 |
| Volume | 1.54M | Market Cap | 3.356B |
| Yield | Last Dividend |
| Attention Biotech Investors: Mark Your C... | 05/01/21 |
| Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NA... | |
| SHAREHOLDER ACTION NOTICE: The Schall La... | 04/26/21 |
| LOS ANGELES , April 26, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action ... | |
| RBC Capital Stick to Their Buy Rating fo... | 04/06/21 |
| RBC Capital Stick to Their Buy Rating for ACADIA Pharmaceuticals Inc | |
| After FDA Rejects Acadia Dementia Drug, ... | 04/06/21 |
| ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) shares came under pressure Monday after the Food and Drug Administration (FDA) rejected its regulatory app... | |
| Tesla, Delta rise; Acadia Pharmaceutical... | 04/05/21 |
| Stocks that traded heavily or had substantial price changes Monday: Tesla, Delta rise; Acadia Pharmaceuticals, Occidental fall | |
| Oppenheimer Stick to Their Hold Rating f... | 04/05/21 |
| Oppenheimer Stick to Their Hold Rating for ACADIA Pharmaceuticals Inc | |
| Acadia Stock Drops After FDA CRL For Pim... | 04/05/21 |
| The FDA has issued a Complete Response Letter (CRL) to Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) regarding its supplemental marketing application (fo... | |
| Attention Biotech Investors: Mark Your C... | 04/02/21 |
| A slew of drugs, including four new molecular entities, were approved in the month of March. NMEs are drugs that contain active moieties that have nev... | |
| The Daily Biotech Pulse: MediciNova Bags... | 03/10/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 9) Amn... | |
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS,... | 03/09/21 |
| SAN FRANCISCO, March 9, 2021 /PRNewswire/ -- Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to sub... | |
| Acadia plummets 49% after FDA decision d... | 03/09/21 |
| Summary List Placement Acadia plummeted as much as 49% on Tuesday after the FDA identified deficiencies in the companies label expansion application f... | |
| Acadia Pharmaceuticals Provides Regulato... | 03/08/21 |
| SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company received a notification from the U.S. Food and... | |
| J.P. Morgan Stick to Their Buy Rating fo... | 03/01/21 |
| J.P. Morgan Stick to Their Buy Rating for ACADIA Pharmaceuticals Inc | |
| Canaccord Genuity Stick to Their Buy Rat... | 02/26/21 |
| Canaccord Genuity Stick to Their Buy Rating for ACADIA Pharmaceuticals Inc | |
| Acadia Pharmaceuticals Reports Fourth Qu... | 02/24/21 |
| SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended De... | |
| A Preview Of ACADIA Pharmaceuticals's Ea... | 02/23/21 |
| On Wednesday, February 24, ACADIA Pharmaceuticals (NASDAQ:ACAD) will release its latest earnings report. Check out Benzinga's preview to understand th... | |
| Acadia Pharmaceuticals Recognizes Nation... | 02/19/21 |
| SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of MoreThanMemoryLoss.com, a new website with educat... | |
| Acadia Pharmaceuticals to Present at Upc... | 02/18/21 |
| SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences:... | |
| Acadia Pharmaceuticals to Announce Fourt... | 02/10/21 |
| SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2020 financial... | |
| Mizuho Securities Stick to Their Buy Rat... | 01/27/21 |
| Mizuho Securities Stick to Their Buy Rating for ACADIA Pharmaceuticals Inc | |
| Acadia Pharmaceuticals Announces Commerc... | 01/27/21 |
| SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Michael Yang, Executive Vice President and Chief Commercia... | |
| Oppenheimer Stick to Their Hold Rating f... | 01/14/21 |
| Oppenheimer Stick to Their Hold Rating for ACADIA Pharmaceuticals Inc | |
| RBC Capital Stick to Their Buy Rating fo... | 01/14/21 |
| RBC Capital Stick to Their Buy Rating for ACADIA Pharmaceuticals Inc | |
| Shuman Glenn & Stecker Investigates Acad... | 01/11/21 |
| DENVER???(BUSINESS WIRE)???Shuman Glenn & Stecker announces that it is investigating potential shareholder claims against certain officers and directo... | |
| Insider Selling: ACADIA Pharmaceuticals ... | 01/10/21 |
| ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) President Srdjan R. Stankovic sold 1,725 shares of ACADIA Pharmaceuticals stock in a transaction that occurr... | |
| Acadia Pharmaceuticals to Present at the... | 11/10/20 |
| SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Stifel 2020 Virtual Healthcare Conf... | |
| RBC Capital Stick to Their Buy Rating fo... | 11/05/20 |
| RBC Capital Stick to Their Buy Rating for ACADIA Pharmaceuticals Inc | |
| Canaccord Genuity Stick to Their Buy Rat... | 11/05/20 |
| Canaccord Genuity Stick to Their Buy Rating for ACADIA Pharmaceuticals Inc | |
| ACADIA Pharmaceuticals Wall street estim... | 11/04/20 |
| ACADIA Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??... | |
| Acadia Pharmaceuticals to Present New Sc... | 10/26/20 |
| SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pima... | |
| Hold rating | 04/07/21 |
| HC Wainwright & Co. downgrades from Buy to Neutral rating and lowers Price Target from $43.00 to $18.00 | |
| Hold rating | 04/06/21 |
| Goldman Sachs downgrades from Buy to Neutral rating and lowers Price Target from $73.00 to $25.00 | |
| Hold rating | 04/06/21 |
| Jefferies downgrades from Buy to Hold rating and lowers Price Target from $40.00 to $21.00 | |
| Hold rating | 04/06/21 |
| Canaccord Genuity downgrades from Buy to Hold rating and lowers Price Target from $40.00 to $26.00 | |
| Hold rating | 04/06/21 |
| Mizuho downgrades from Buy to Neutral rating and announces Price Target of $25.00 | |
| Strong Buy rating | 04/06/21 |
| Morgan Stanley maintains Overweight rating and lowers Price Target from $50.00 to $28.00 | |
| Buy rating | 04/05/21 |
| Needham maintains Buy rating and lowers Price Target from $44.00 to $30.00 | |
| Buy rating | 03/09/21 |
| HC Wainwright & Co. maintains Buy rating and lowers Price Target from $60.00 to $43.00 | |
| Buy rating | 03/09/21 |
| Needham maintains Buy rating and lowers Price Target from $60.00 to $44.00 | |
| Hold rating | 03/09/21 |
| Stifel downgrades from Buy to Hold rating and lowers Price Target from $68.00 to $27.00 | |
| Strong Buy rating | 03/09/21 |
| Raymond James downgrades from Strong Buy to Outperform rating and lowers Price Target from $65.00 to $35.00 | |
| Strong Buy rating | 03/09/21 |
| Morgan Stanley maintains Overweight rating and lowers Price Target from $65.00 to $50.00 | |
| Buy rating | 03/09/21 |
| Canaccord Genuity maintains Buy rating and lowers Price Target from $61.00 to $40.00 | |
| Hold rating | 03/09/21 |
| Citigroup downgrades from Buy to Neutral rating and lowers Price Target from $66.00 to $35.00 | |
| Strong Buy rating | 02/25/21 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $60.00 to $65.00 | |
| Date | 2021-02-24 (AMC) | Est. (EPS/Rev.) | ($0.47)/ 123.2M |
| Actual (EPS/Rev.) | $-0.42/ $121.01 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Trading Systems | Trading Systems | 83.00 % | Subscribe |
| Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
| Arbitrage Trade Analytics | Royce Wells | 72.00 % | Subscribe |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Best Trading Ideas | Best Trading Ideas | 53.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
